A review of tositumomab and I131 tositumomab radioimmunotherapy for the treatment of follicular lymphoma

Expert Opinion on Biological Therapy

Volumn 5, Issue 4, 2005, Pages 577-588

  Davies, Andrew J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

CD20; Follicular lymphoma; Iodine I131 tositumomab; Monoclonal antibody; Radioimmunotherapy; Tositumomab

Indexed keywords

ANTIHISTAMINIC AGENT; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; LUGOL; PARACETAMOL; POTASSIUM IODIDE; PREDNISOLONE; PREDNISONE; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; VINCRISTINE;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ANAPHYLAXIS; ANEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; APOPTOSIS; ASTHENIA; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CHILL; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; COUGHING; DOSIMETRY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TARGETING; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HUMAN; INFECTION; IONIZING RADIATION; MYELODYSPLASIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RADIOIMMUNOTHERAPY; RADIOIODINATION; RADIOSENSITIVITY; RASH; REVIEW; THROMBOCYTOPENIA; VOMITING; WHOLE BODY RADIATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA, FOLLICULAR; RADIOIMMUNOTHERAPY;

MURINAE;

EID: 17944366954     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.4.577     Document Type: Review

References (83)

1. THE NON-HODGKIN'S LYMPHOMA CLASSIFICATION PROJECT: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood (1997) 89:3909-3918.
2. HORNING SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin. Oncol. (1993) 20:75-88.
3. GALLAGHER CJ, GREGORY WM, JONES AE et al.: Follicular lymphoma: prognostic factors for response and survival. J. Clin. Oncol. (1986) 4:1470-1480.
4. JOHNSON PW, ROHATINER AZ, WHELAN J et al.: Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J. Clin. Oncol. (1995) 13:140-147.
5. MACMANUS MP, HOPPE RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J. Clin. Oncol. (1996) 14:1282-1290.
6. BRICE P, BASTION Y, LEPAGE E et al.: Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. (1997) 15:1110-1117.
7. ARDESHNA KM, SMITH P, NORTON A et al.: Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet (2003) 362:516-522.
8. ADVANI R, ROSENBERG SA, HORNING SJ: Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J. Clin. Oncol. (2004) 22:1454-1459.
9. HORNING SJ: Follicular lymphoma: have we made any progress? Ann. Oncol. (2000) 11(Suppl. 1):23-27.
10. CABANILLAS F, HORNING S, KAMINSKI M, CHAMPLIN R: Managing indolent lymphomas in relapse: working our way through a plethora of options. Hematol. (Am. Soc. Hematol. Educ. Program) (2000):166-179.
11. SOLAL-CELIGNY P, ROY P, COLOMBAT P et al.: Follicular lymphoma international prognostic index. Blood (2004) 104:1258-1265.
12. DAVE SS, WRIGHT G, TAN B et al.: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. (2004) 351:2159-2169.
13. STASHENKO P, NADLER LM, HARDY R, SCHLOSSMAN SF: Characterization of a human B lymphocyte-specific antigen. J. Immunol. (1980) 125:1678-1685.
14. EINFELD DA, BROWN JP, VALENTINE MA, CLARK EA, LEDBETTER JA: Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. (1988) 7:711-717.
15. TEDDER TF, STREULI M, SCHLOSSMAN SF, SAITO H: Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc. Natl. Acad. Sci. USA (1988) 85:208-212.
16. BUBIEN JK, ZHOU LJ, BELL PD, FRIZZELL RA, TEDDER TF: Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J. Cell Biol. (1993) 121:1121-1132.
17. LI H, AYER LM, LYTTON J, DEANS JP: State-operated cation entry mediated by CD20 in membrane rafts. J. Biol. Chem. (2003) 278:42427-42434.
18. ANDERSON KC, BATES MP, SLAUGHENHOUPT BL, PINKUS GS, SCHLOSSMAN SF, NADLER LM: Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood (1984) 63:1424-1433.
19. MCLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. (1998) 16:2825-2833.
20. HIDDEMANN W, DREYLING MH, FORSTPOINTNER R et al.: Combined immune-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood (2003) 102:104a (abstract).
21. FORSTPOINTNER R, DREYLING M, REPP R et al.: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxanrrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood (2004) 104:3064-3071.
22. MARCUS R, IMRIE K, BELCH A et al.: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood (2004) 105(4):1417-1423.
23. TEDDER TF, FORSGREN A, BOYD AW, NADLER LM, SCHLOSSMAN SF: Antibodies reactive with the BI molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur. J. Immunol. (1986) 16:881-887.
24. BUCHSBAUM DJ, WAHL RL, NORMOLLE DP, KAMINSKl MS: Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res. (1992) 52:6476-6481.
25. SHAN D, LEDBETTER JA, PRESS OW: Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood (1998) 91:1644-1652.
26. CRAGG MS, GLENNIE MJ: Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood (2004) 103:2738-2743.
27. SHAN D, LEDBETTER JA, PRESS OW: Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol. Immunother. (2000) 48:673-683.
28. 131 tositumomab.
29. FRAKER PJ, SPECK JC JR: Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem. Biophys. Res. Commun. (1978) 80:849-857.
30. O'DONOGHUE J, BARDIES M, WHELDON T: Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J. Nucl. Med. (1995) 36:1902-1909.
31. KASSIS A, ADELSTEIN S: Considerations in the selection of Radionuclides for cancer therapy. In: Handbook of Radiopharmaceuticals: Radiochemistry and Applications. Welch M, Redvanly C (Eds), John Wiley Publishers, West Sussex, UK (2003):767-793.
32. GLAXOSMITHKLINE: GluxoSmithKline Announces Expanded Indication for Bexxar in Non-Hodgkin's Lymphoma. (2005) Press Release.
33. KAMINSKl MS, ZASADNY KR, FRANCIS IR et al.: Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med. (1993) 329:459-465.
34. BUCHSBAUM DJ, WAHL RL, GLENN SD, NORMOLLE DP, KAMINSKI MS: Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosmg with unlabeled anti-B1 monoclonal antibody. Cancer Res. (1992) 52:637-642.
35. KAMINSKI MS, ZASADNY KR, FRANCIS IR et al.: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol. (1996) 14:1974-1981.
36. MONES J, COLEMAN M, KOSTAKOGLU L et al.: A dose-escalation study of tositumomab and iodine I 131 tosituniomab (Bexxar) in pts with previously treated non-Hodgkin's lymphoma (NHL) with > 25% bone marrow involvement. Proc. Am. Soc. Clin. Oncol. (2004) 23:574 (abstract).
37. SIEGEL JA: Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-B1 therapy. J. Nucl. Med. (1998) 39:28S-33S.
38. WAHL RL: The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Semin. Oncol. (2003) 30:31-38.
39. GOLDSMITH SJ, KAMINSKI M, WAHL RL et al.: Dosimetry optimizes radiolabelled antibody dosing in patients with non-Hodgkin's lymphoma. Proc. Am. Soc. Clin. Oncol. (2001) 19:1140 (abstract).
40. KAMINSKI MS, ESTES J, ZASADNY KR et al.: Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term Follow-up of the University of Michigan experience. Blood (2000) 96:1259-1266. Complete data and long-term follow-up of the Phase I/II study from a single centre.
41. WAHL RL: Iodine-131 anti-B1 antibody therapy in non-Hodgkin's lymphoma: dosimetry and clinical implications. J. Nucl. Med. (1998) 39:1S.
42. VOSE JM, WAHL RL, SALEH M et al.: Multicenter Phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. (2000) 18:1316-1323. First multi-centre study, demonstrates reproducibility of dosimetric methodology.
43. 131 tositumomab than from their previous chemotherapeutic regimen.
44. 131 tositumomab (the BEXXAR therapeutic regimen) produced ongoing, durable remissions of more than 4 years in 9 patients with non-Hodgkin's lymphoma (NHL) in a pivotal study of patients refractory to their last chemotherapy. Blood (2004) 104:720a (abstract).
45. 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. (2004) 22:1469-1479.
46. LEONARD J, FRENETT G, DILLMAN RO, GREGORY SA: Interim safety and efficacy results of Bexxar™ in a large multicenter expanded access study. Blood (2001) 98:133a (abstract).
47. ARMITAGE JO, LEONARD J, GREGORY SA et al.: The effectiveness of tositumomab and iodine I 131 tositumomab in relapsed/refractory follicular grade 1/2 and small lymphocytic non-Hodgkin's lymphoma (NHL). Proc. Am. Soc. Clin. Oncol. (2004) 23:573 (abstract).
48. HORNING SJ, YOUNES A, JAIN V et al.: Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J. Clin. Oncol. (2004) 23(4):712-719. Recent analysis of rituximab-refractory patients.
49. 131 tositumomab) produced durable complete remissions in heavily pretreated patients with non-Hodgkins lymphoma (NHL), rituximab-relapsed/refractory disease, and rituximab-naive disease. Blood (2003) 102:29a (abstract).
50. 131 tositumomab) and with chemotherapy. Blood (2004) 104:41a (abstract).
51. ARMITAGE JO, DICK FR, CORDER MP: Diffuse histiocytic lymphoma after histologic conversion: a poor prognostic variant. Cancer Treat. Rep. (1981) 65:413-418.
52. 131 tositumomab [Bexxar®]. Blood (2002) 100:357a (abstract).
53. KAMINSKI MS, TUCK M, ESTES J et al.: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. (2005) 352(5):441-449.
54. BENNETT JM, KAMINSKI M, KNOX SJ et al.: Assessment of treatment-related myeloclysplastic syndromes (tMDS) and acute myeloid leukemia (tAML) in patients with low-grade non-Hodgkins lymphoma (LG-NHL) treated with tositumomab and iodine-131 tositumomab (the BEXXAR therapeutic regimen). Blood (2003) 102:30a (abstract).
55. 131 tositumomab (the BEXXAR therapeutic regimen) in patients with non-Hodgkins lymphoma (NHL) with a previous response to the BEXXAR therapeutic regimen. Blood (2003) 102:407a (abstract).
56. CZUCZMAN MS, GRILLO-LOPEZ AJ, WHITE CA et al.: of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. (1999) 17:268-276.
57. LEONARD J, COLEMAN M, KOSTAKOGLU L et al.: Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkins lymphoma (NHL). Proc. Am. Soc. Clin. Oncol. (2004) 23:560 (abstract).
58. 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma (NHL). Proc. Am. Soc. Clin. Oncol. (2004) 23:560 (abstract).
59. 131 I-tositumomab followed by CHOP chemotherapy results in a high complete remission rate. Blood (2003) 102:406a (abstract).
60. PRESS OW, EARY JF, APPELBAUM FR et al.: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. (1993) 329:1219-1224.
61. PRESS OW, EARY JF, APPELBAUM FR et al.: Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet (1995) 346:336-340.
62. GOPAL AK, GOOLEY TA, MALONEY DG et al: High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoictic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood (2003) 102:2351-2357.
63. PRESS OW, EARY JF, GOOLEY T et al.: A Phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood (2000) 96:2934-2942.
64. VOSE JM, BIERMAN PJ, ENKE C et al.: Phase 1 trial of iodinc-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. (2004) 23(3):461-467.
65. GLAXOSMITHKLINE: BEXXAR® Prescribing Information (2005).
66. GREGORY SA, ZELENETZ AD, KNOX SJ, VOSE JM, MAGNUSON, KAMINSKI MS: Bexxar™ is an effective and well tolerated therapy in elderly patients with non-Hodgkin's lymphoma (NHL). Proc. Am. Soc. Clin. Oncol. (2001) 20:285a (abstract).
67. ARMITAGE JO, CARBONE PP, CONNORS JM, LEVINE A, BENNETT JM, KROLL S: Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J. Clin. Oncol. (2003) 21:897-906.
68. GREGORY SA, LEONARD J, KNOX SJ, ZELENETZ AD, ARMITAGE JO, KAMINSKI M: The iodine I-131 tositumomab therapeutic regimen: summary of safety in 995 patients with relapsed/refractory low grade (LG) and transformed LG non-Hodgkin's lymphoma (NHL). Proc. Am. Soc. Clin. Oncol. (2004) 23:613 (abstract).
69. KAMINSKI MS, TUCK M, FANG Y, COLCHER D, VALENTE NK, NIEDER M: Development of HAMA after Bexxar™ does not preclude treatment with rituximab. Blood (2000) 96:734a (abstract).
70. VALENTE NK, KAMINSKI M, KNOX SJ et al.: Subsequent therapy can be administered following treatment with iodine 131 anti-B1 antibody in patients with non-Hodgkin's lymphoma. Ann. Oncol. (1999) 10:33 (abstract).
71. 131 tositumomab (Bexxar™). Blood (2001) 98:200a (abstract).
72. KAMINSKI MS, BAHM V, ESTES J, RATANATHARATHORN V: Tolerance of treatment subsequent to frontline Bexxar™ (tositumomab and I 131 tositumomab) in patients with follicular lymphoma. Blood (2001) 98:603a (abstract).
73. CHESON BD: Some like it hot! J. Clin. Oncol. (2001) 19:3908-3911.
74. DILLMAN RO: Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J. Clin. Oncol. (2002) 20:3545-3557.
75. CHESON BD: Radioimmunotherapy of non-Hodgkin lymphomas. Blood (2003) 101:391-398. Comprehensive review of radioimmunotherapy of non-Hodgkin's lymphomas.
76. CORIXA CORPORARTION: Corixa announces sale and transfer of BEXXAR development and marketing rights to GlaxoSmithKline. (2004). Press Release.
77. SCHOUTEN HC, QIAN W, KVALOY S et al.: High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results ftom the randomized European CUP trial. J. Clin. Oncol. (2003) 21:3918-3927.
78. KHOURI IF, SALIBA RM, GIRALT SA et al.: Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood (2001) 98:3595-3599.
79. WITZIG TE, WHITE CA, WISEMAN GA et al.: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. (1999) 17:3793-3803.
80. WITZIG TE, FLINN IW, GORDON LI et al.: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol. (2002) 20:3262-3269.
81. WISEMAN GA, GORDON LI, MULTANI PS et al.: Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a Phase II multicenter trial. Blood (2002) 99:4336-4342.
82. WITZIG TE, GORDON LI, CABANILLAS F et al.: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. (2002) 20:2453-2463.
83. VOSE JM, LINK BK, GROSSBARD ML et al.: Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. (2001) 19:389-397.